AIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AIM ImmunoTech Inc is not a good buy for a beginner investor with a long-term strategy at this time. The stock has shown significant negative price movement, poor financial performance, and lacks positive catalysts or strong trading signals. It is better to wait for clearer signs of recovery or positive momentum before considering an investment.
The stock is currently in a bearish trend with a significant regular market drop of -18.90%. The RSI is neutral at 31.703, and the MACD is positively contracting but still above 0. The moving averages are converging, and the price is near the S1 support level of 0.685, indicating potential further downside risk.
NULL identified. No recent news or significant insider or hedge fund activity.
The stock experienced a sharp decline in both pre-market (-11.45%) and regular market (-18.90%) trading. Financial performance in Q3 2025 was poor, with revenue, net income, EPS, and gross margin all showing significant declines. No positive trading trends or signals were identified.
In Q3 2025, AIM ImmunoTech reported a 25.71% YoY drop in revenue to $26,000, a net income loss of -$3,284,000 (down 11.24% YoY), and a steep decline in EPS (-75.51% YoY). The gross margin also fell significantly to -161.54%, down 309.41% YoY. These metrics indicate weak financial health and poor growth trends.
No recent analyst ratings or price target updates available.
